Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study-Reference-Cited by-同舟云学术

Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study

Published:2016-11 Issue: Volume:62 Page:54-59
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

del Barco Morillo Elvira,Mesía Ricard,Adansa Klain Juan Carlos,Vázquez Fernández Silvia,Martínez-Galán Joaquina,Pastor Borgoñon Miguel,González-Rivas Cyntia,Caballero Daroqui Javier,Berrocal Alfonso,Martínez-Trufero Javier,Vera Ruth,Cruz-Hernández Juan Jesús

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference24 articles.

1. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment;Marur;Mayo Clin Proc,2016

2. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck;Colevas;J Clin Oncol Off J Am Soc Clin Oncol,2006

3. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study;Schena;Cancer Chemother Pharmacol,2005

4. Expanding role of the medical oncologist in the management of head and neck cancer;Choong;CA Cancer J Clin,2008

5. Present and future of EGFR inhibitors for head and neck squamous cell cancer;Baba;J Oncol,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer;Pharmaceutics;2024-09-11

2. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody;ESMO Open;2024-06

3. A scoping review of utilisation of the EQ-5D questionnaire to evaluate health-related quality of life following a diagnosis of head and neck cancer;Frontiers of Oral and Maxillofacial Medicine;2024-03

4. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04

5. Targeted therapy for head and neck cancer: signaling pathways and clinical studies;Signal Transduction and Targeted Therapy;2023-01-16